Hanmi, MSD to cooperate over Amosartan

Published: 2011-05-20 06:56:00

Updated: 2011-05-20 06:56:00

Hanmi Pharmaceutical and the US based Merck & Co. signed their second contract to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in 30 countries, under Merck's brand Cozzar XQ.

The company earlier signed a contract with Merck for overseas licensing out agreement ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK